OakChart

Tectonic Therapeutic Inc

TECXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

21.96-0.01 (-0.05%)
2026-11-12 05:57 CET
Market cap
438.06 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-88.10 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-4.63
P/E
-
Compare

Price

TECX against its 20, 50 and 200-day averages
2050200beat
20.0025.0030.0035.0040.00525K1.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TECXclose 21.9620-day 20.6650-day 23.67200-day 28.1321.9652w high

44.4% under the 52-week high of 39.53 on 6 Jul 2026. 52-week low 16.77 on 10 Feb 2026. Last 15 sessions, 23.0% high to low

Volume 0.60× normal · the line is the 50-bar volume average

Profile

TECX
52-week range, 23% of the way up
16.7739.53

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

IndexRUT
Employees60
IPOJun 21, 2018
Beta1.24
ATR, 14d1.32
Rel volume0.60
Short float22.91%
Insider own48.00%
Inst own58.06%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap438.06M
Enterprise Value207.79M
Income-88.10M
Sales0.00M
Book/sh11.64
Cash/sh11.76
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees60
IPOJun 21, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.89
P/C1.87
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio22.29
Current Ratio22.29
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.63
EPS next Y-5.31
EPS next Q-1.38
EPS this Y-22.24%
EPS next Y-7.28%
EPS next 5Y-14.32%
EPS past 3/5Y48.16% 36.65%
Sales past 3/5Y- -
EPS Y/Y TTM-20.25%
Sales Y/Y TTM-
EPS Q/Q-6.51%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.17.95% -

Ownership

Insider Own48.00%
Insider Trans-0.01%
Inst Own58.06%
Inst Trans-3.16%
ROA-33.83%
ROE-35.46%
ROIC-38.87%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.29%
SMA50-7.21%
SMA200-21.93%
Trades-

Technical

Shs Outstand19.95M
Shs Float10.37M
Short Float22.91%
Short Ratio10.66
Short Interest2.38M
52W High39.53 -44.44%
52W Low16.77 30.95%
Volatility7.51% 5.93%
ATR (14)1.32
RSI (14)51.95
Beta1.24
Rel Volume0.60
Avg Volume222.85K
Volume134,232

Performance

Perf Week8.18%
Perf Month3.05%
Perf Quarter-35.37%
Perf Half Y-23.78%
Perf YTD5.27%
Perf Year15.70%
Perf 3Y33.58%
Perf 5Y-65.79%
Perf 10Y-
Recom1.20
Target Price71.00
Prev Close21.97
Price21.96
Change %-0.05%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedUUBSNeutral$26+18.4%
May 26, 2026UpgradeRRaymond JamesOutperform → Strong Buy$81+268.9%
Apr 14, 2026InitiatedSStifelBuy$75+241.5%
Oct 20, 2025InitiatedWWells FargoOverweight$101+359.9%
Sep 03, 2025InitiatedOOppenheimerOutperform$80+264.3%
Jul 21, 2025InitiatedTTruistBuy$64+191.4%
Jun 11, 2025ResumedRRaymond JamesOutperform$76+246.1%
Apr 21, 2025InitiatedMMizuhoOutperform$51+132.2%
Nov 20, 2024InitiatedRRaymond JamesOutperform$65+196.0%
Aug 22, 2024InitiatedWWells FargoOverweight$55+150.5%

Peers

Mkt cap
TickerCompanyMkt cap
GPCRStructure Therapeutics Inc ADR1.49B
SEPNSepterna Inc2.31B
BRVEBraveheart Bio Inc1.88B
KARDKardigan Inc1.47B
CYTKCytokinetics Inc8.15B
RNAAtrium Therapeutics Inc177.32M
EWTXEdgewise Therapeutics Inc5.21B
MLYSMineralys Therapeutics Inc1.43B
ATTOAttovia Therapeutics Inc764.77M
TNYATenaya Therapeutics Inc84.61M

Insider trading

latest 14 of 29
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
REICIN ALISEChief Executive OfficerOct 26 '26Option Exercise2.3810,00023,800319,078Oct 28 04:30 PM
McNamara PeterChief Scientific OfficerSep 30 '26Sale23.0453612,34954,305Oct 02 05:00 PM
PETER MCNAMARAOfficerSep 30 '26Proposed Sale23.3449311,507Sep 30 04:21 PM
TERRANCE MCGUIREFormer DirectorAug 27 '26Proposed Sale36.837,513276,718Aug 27 05:20 PM
McNamara PeterChief Scientific OfficerAug 25 '26Option Exercise14.714363355,328Aug 26 04:30 PM
McNamara PeterChief Scientific OfficerAug 25 '26Sale36.52431,57055,285Aug 26 04:30 PM
TERRANCE MCGUIREFormer DirectorAug 21 '26Proposed Sale37.6110,200383,671Aug 21 05:58 PM
McNamara PeterChief Scientific OfficerAug 12 '26Option Exercise14.714363355,328Aug 14 07:25 PM
McNamara PeterChief Scientific OfficerAug 12 '26Sale35.00431,50555,285Aug 14 07:25 PM
PETER MCNAMARAOfficerAug 12 '26Proposed Sale31.871294,111Aug 12 04:37 PM
McNamara PeterChief Scientific OfficerJun 30 '26Option Exercise14.711722,53055,457Jul 01 05:19 PM
McNamara PeterChief Scientific OfficerJun 30 '26Sale35.001726,02055,285Jul 01 05:19 PM
PETER MCNAMARAOfficerJun 30 '26Proposed Sale33.091725,691Jun 30 04:38 PM
Ruddy Marcella K.Chief Medical OfficerMay 04 '26Sale30.001,06531,95067,682May 06 05:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • Tectonic Therapeutic to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.06%
  • Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) +6.28%
  • Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) (GlobeNewswire)
  • Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
  • Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients (GlobeNewswire)
  • Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -7.41% +7.93%
  • Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors (GlobeNewswire)
  • Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
  • Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
  • Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins (MarketBeat) +8.24%
  • Tectonic Therapeutic Appoints Francois Nader, M.D., as Chair and Independent Director of the Board (GlobeNewswire)
  • Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 (GlobeNewswire)
  • Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating (Insider Monkey)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.080-1.316-1.0800.000.009
2026Q22026-08-06-1.180-1.349-1.1750.000.009
2026Q12026-05-07-1.340-1.165-1.3450.000.009
2025Q42026-02-26-1.030-1.088-1.0270.000.008
2025Q32025-11-06-1.020-1.056-1.0170.000.008
2025Q22025-08-07-1.070-0.977-1.0700.000.007
2025Q12025-05-08-0.930-1.086-0.9270.000.005
2024Q42025-03-20-0.840-1.387-0.8360.000.003
2024Q32024-11-07-1.200-0.840-1.2030.000.003
2024Q22024-08-14-4.340-1.303-4.3400.000.003
2024Q12024-05-09-1.943-4.320-1.8240.00-1
2023Q32023-11-09-5.760-4.224-5.8150.00-4
2023Q22023-08-1018.240-6.49118.2860.000.004
2023Q12023-05-11-6.840-6.540-6.8010.000.008
2022Q42023-03-23-6.840-5.915-6.8610.000.008
2022Q32022-11-08-6.240-6.600-6.2970.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-31.920-30.048-31.9180.000.00
2020FY-39.720-41.190-39.6770.000.00
2021FY-33.360-34.417-33.3580.000.00
2022FY-29.040-27.582-29.0510.000.00
2023FY-18.0401.500-33.7580.000.00
2024FY-6.830-8.075-6.8290.000.00
2025FY-4.050-4.166-4.0500.000.00
2026FY--4.951--0.00
2027FY--5.311--0.00
2028FY--6.051--0.00
2029FY--6.307--140
2030FY--4.191--161.25

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-065000.000.000.00
2026Q4S2026-10-095000.000.000.00
2026Q4S2026-09-144000.000.000.00
2026Q4S2026-08-075000.000.000.00
2026Q4S2026-05-085000.000.000.00
2026Q4S2026-02-275000.000.000.00
2026Q4S2025-12-293000.000.000.00
2026Q4S2025-11-162000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-103000.000.000.00
2026Q4S2025-11-093000.000.000.00
2026Q4S2025-11-083000.000.000.00
2026Q4S2025-11-073000.000.000.00
2026Q4S2025-11-063000.000.000.00

Estimate history

EPS, annual-9.391-43.411-31.918-39.677-33.358-29.051-33.758-6.829-4.047-4.6304
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.203-0.836-0.927-1.07-1.017-1.027-1.345-1.175-1.083
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.9951.9842.6373.4643.6383.661.40814.85618.73819.235
Period201720182019202020212022202320242025MRQ
Shares, quarterly14.74414.85618.67118.71218.71318.73818.8319.235-
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.003.491.651.484.171.401.210.850.38
Gross Profit0.00-3.49-1.65-1.48-4.17-1.40-1.21-0.85-0.38
Selling, General and Administrative Excl. Other94.1080.5456.3743.17101.27117.44119.0274.9645.86
Research and Development71.9162.4941.3636.9768.0281.7286.0354.9735.09
Other Operating Expense-0.000.000.000.000.000.000.000.00
Operating Income-96.49-84.04-58.02-44.65-105.43-118.84-120.23-75.81-46.24
Interest Expense0.030.060.110.150.300.220.000.000.00
Unusual Expense-0.003.61-1.000.000.000.000.001.79
Net Income Before Taxes-87.77-72.92-57.98-42.82-105.89-119.13-119.71-72.97-46.36
Income Taxes0.331.230.000.000.000.000.000.000.00
Consolidated Net Income-88.10-74.15-57.98-42.82-105.89-119.13-119.71-72.97-46.36
Net Income From Continuing Operations-88.10-74.15-57.98-42.82-105.89-119.13-119.71-72.97-46.36
Net Income-88.10-74.15-57.98-42.82-105.89-119.13-119.71-72.97-48.60
EPS (Recurring)-4.47-4.05-6.53-34.31-29.05-33.36-39.68-31.92-42.29
EPS (Basic, Before Extraordinaries)-4.63-4.05-6.83-33.76-29.05-33.36-39.68-31.92-43.41
EPS (Diluted)-4.63-4.05-6.83-33.76-29.05-33.36-39.68-31.92-43.41
EBITDA--80.54-56.37-43.17-101.27-117.44-119.02-74.96-45.86
Non-Operating Income (Expense)8.7611.183.750.98-0.16-0.060.522.841.67
Other After Tax Adjustments-0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-8.293.490.8911.5218.5815.636.802.20
Shares Outstanding-18.7414.861.413.663.643.462.641.98
Market Capitalization438.06438.06681.1360.6031.21168.06579.47636.97396.38

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.710.800.880.340.340.360.51
Gross Profit0.00-0.71-0.80-0.88-0.34-0.34-0.36-0.51
Selling, General and Administrative Excl. Other23.4623.5026.5020.6421.5521.9917.9413.48
Research and Development17.4417.7620.5716.1416.7316.9812.749.15
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income-23.46-24.22-27.30-21.52-21.89-22.33-18.30-13.99
Interest Expense0.000.010.010.010.010.020.020.02
Unusual Expense-0.000.000.000.000.000.000.00
Net Income Before Taxes-21.35-22.21-25.24-18.97-19.04-19.01-15.91-12.37
Income Taxes0.000.080.000.250.000.980.000.00
Consolidated Net Income-21.35-22.29-25.24-19.23-19.04-19.98-15.91-12.37
Net Income From Continuing Operations-21.35-22.29-25.24-19.23-19.04-19.98-15.91-12.37
Net Income-21.35-22.29-25.24-19.23-19.04-19.98-15.91-12.37
EPS (Recurring)-1.08-1.18-1.34-1.03-1.02-1.07-0.93-0.84
EPS (Basic, Before Extraordinaries)-1.08-1.18-1.34-1.03-1.02-1.07-0.93-0.84
EPS (Diluted)-1.08-1.18-1.34-1.03-1.02-1.07-0.93-0.84
EBITDA--23.50-26.50-20.64-21.55-21.99-17.94-13.48
Non-Operating Income (Expense)2.122.022.072.562.873.342.411.64
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense-3.173.212.362.822.042.101.12
Shares Outstanding-19.2418.8318.7418.7118.7118.6714.86
Market Capitalization438.06648.63580.38390.42293.59371.02330.52681.13

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments254.38141.2428.7792.85189.57259.68187.04126.305.96
Short Term Receivables0.000.000.000.272.702.562.141.540.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.975.622.126.846.885.006.522.170.34
Total Current Assets257.36146.8630.8899.96199.15267.24195.70130.026.31
Net Property, Plant & Equipment2.555.307.233.954.133.063.702.630.35
Total Investments and Advances0.480.590.590.000.490.490.490.490.02
Intangible Assets--0.00------
Other Assets0.640.160.700.040.070.440.620.330.34
Total Assets261.04152.9139.40103.95203.84271.23200.51133.487.02
Short Term Debt Incl. Current Port. of LT Debt1.232.781.821.000.000.000.000.000.00
Accounts Payable1.090.980.410.383.492.683.952.780.53
Other Current Liabilities7.347.8538.6611.7315.9013.9310.077.822.10
Total Current Liabilities9.6711.6140.8913.1219.3916.6114.0210.612.62
Long Term Debt0.040.5283.1515.4614.950.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.030.280.480.691.03
Total Liabilities9.7112.13124.0328.5834.3616.8914.5011.293.66
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0026.50
Common Equity251.33140.78-84.6475.37169.48254.34186.01122.18-23.14
Total Shareholders Equity251.33140.78-84.6475.37169.48254.34186.01122.183.37
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity251.33140.78-84.6475.37169.48254.34186.01122.183.37
Total Liabilities & Stockholders Equity261.04152.9139.40103.95203.84271.23200.51133.487.02
Book Value Per Share13.419.48-60.1220.5946.5973.4270.5461.59-11.60
Tangible Book Value Per Share13.419.48-60.1220.5946.5973.4270.5461.59-11.60
Full-Time Employees60511378122121854924
Price to Book Ratio1.894.530.590.320.992.283.423.242.90
Return on Assets-35.83-45.66-59.75-68.81-50.15-50.75-43.69-65.99-300.24
Return on Equity-37.82-49.2414.29-86.50-56.22-54.37-47.35-73.85-479.01
Return on Invested Capital-29.50-41.04--116.58-64.59-47.07-39.23-37.94-554.18
Quick Ratio26.6312.650.767.6210.2716.0913.9612.262.40
Current Ratio26.6312.650.767.6210.2716.0913.9612.262.40

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--74.15-57.98-42.82-105.89-119.13-119.71-72.97-46.36
Depreciation-3.491.651.484.171.401.210.850.38
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)-10.657.541.2511.9218.4115.466.634.15
Funds from Operations--60.01-48.80-40.10-89.81-99.32-103.04-65.49-41.83
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--0.07-10.28-0.58-7.401.304.24-2.184.18
Cash from Operating Activities--60.08-59.08-40.68-97.21-98.03-98.80-67.67-37.65
Capital Expenditures--0.21-0.16-0.28-0.27-2.46-1.18-1.58-1.83
Net Assets From Acquisitions-0.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses-0.070.000.000.000.000.000.00-
Purchase or Sale of Investments-0.000.000.000.000.000.000.000.00
Purchase of Investments-0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.000.000.000.00
Other Uses-0.000.000.000.000.000.000.000.00
Other Sources-0.000.000.000.000.000.000.000.00
Cash from Investing Activities--0.14-0.16-0.28-0.27-2.46-1.18-1.58-1.83
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Change in Capital Stock-174.3396.220.120.2615.47172.62129.99160.29
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-174.3396.220.120.2615.47172.62129.99160.29
Proceedsfrom Stock Options-173.1094.600.000.2014.55172.35129.47160.27
Issuance or Reduction of Debt, Net--0.49-0.47-0.500.0014.900.000.000.00
Change in Long Term Debt--0.49-0.47-0.500.0014.900.000.000.00
Issuance of Long Term Debt-0.000.000.000.0014.900.000.000.00
Reduction of Long Term Debt--0.49-0.47-0.500.000.000.000.000.00
Net Financing Active Other Cash Flow--0.4875.9734.120.000.000.000.000.00
Other Financing Activities Uses--0.480.000.000.000.000.000.000.00
Cash from Financing Activities-173.35171.7133.750.2630.37172.62129.99160.29
Exchange Rate Effect--0.10-0.010.02-----
Net Change in Cash-113.04112.47-7.20-97.21-70.1172.6460.74120.81
Free Cash Flow--60.29-59.24-40.96-97.47-100.49-99.98-69.25-39.48

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments234.67227.07236.89254.38269.02287.38
Short Term Receivables-0.000.000.000.000.00
Inventories-0.000.000.000.000.00
Other Current Assets-4.033.002.974.223.47
Total Current Assets-231.10239.89257.36273.24290.85
Net Property, Plant & Equipment-4.835.542.552.683.59
Total Investments and Advances-0.480.480.480.480.59
Other Assets-0.630.660.640.600.29
Total Assets243.86237.03246.58261.04277.00295.31
Short Term Debt Incl. Current Port. of LT Debt-1.581.431.231.141.76
Accounts Payable-1.682.551.091.492.80
Other Current Liabilities-7.118.977.346.756.80
Total Current Liabilities-10.3712.969.679.3711.36
Long Term Debt-2.823.200.040.100.19
Provision for Risks Charges-0.000.000.000.000.00
Other Liabilities-0.000.000.000.000.00
Total Liabilities-13.1916.169.719.4711.55
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity229.32223.85230.42251.33267.53283.77
Total Shareholders Equity229.32223.85230.42251.33267.53283.77
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity229.32223.85230.42251.33267.53283.77
Total Liabilities & Stockholders Equity-237.03246.58261.04277.00295.31
Book Value Per Share-11.6412.2413.4114.3015.16
Tangible Book Value Per Share-11.6412.2413.4114.3015.16
Full-Time Employees---60--
Price to Book Ratio1.892.562.301.461.031.23
Return on Assets-33.83-32.23-29.74-35.83-30.20-26.97
Return on Equity-35.46-33.80-31.42-37.82-32.21-29.32
Return on Invested Capital--9.83-10.80-7.65-7.11-7.04
Quick Ratio-22.2918.5126.6329.1525.60
Current Ratio-22.2918.5126.6329.1525.60

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income--22.29-25.24-19.23-19.04-19.98
Depreciation-0.710.802.450.340.34
Other Funds (Non Cash)-4.013.231.423.443.17
Funds from Operations--17.56-21.21-15.36-15.25-16.47
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital--3.892.800.90-2.571.75
Cash from Operating Activities--21.45-18.41-14.46-17.82-14.72
Capital Expenditures--0.08-0.020.00-0.180.00
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.020.000.000.010.06
Purchase or Sale of Investments-0.000.000.000.000.00
Purchase of Investments-0.000.000.000.000.00
Sale Or Maturity of Investments-0.000.000.000.000.00
Other Uses-0.000.000.000.000.00
Other Sources-0.000.000.000.000.00
Cash from Investing Activities--0.06-0.020.00-0.170.06
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-11.861.360.45-0.39-3.98
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-11.861.360.45-0.39-3.98
Proceedsfrom Stock Options-11.811.260.40-0.40-4.17
Issuance or Reduction of Debt, Net--0.10-0.10-0.13-0.12-0.12
Change in Long Term Debt--0.10-0.10-0.13-0.12-0.12
Issuance of Long Term Debt-0.000.000.000.000.00
Reduction of Long Term Debt--0.10-0.10-0.13-0.12-0.12
Net Financing Active Other Cash Flow--0.08-0.41-0.470.06-0.07
Other Financing Activities Uses--0.08-0.41-0.470.06-0.07
Cash from Financing Activities-11.680.85-0.14-0.46-4.17
Exchange Rate Effect-0.000.09-0.04-0.02-0.03
Net Change in Cash--9.83-17.49-14.64-18.46-18.86
Free Cash Flow--21.53-18.43-14.46-18.00-14.72

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3022.91%2.4M10.4M219.57K
2026-10-1521.87%2.2M10.2M216.21K
2026-09-3021.85%2.2M10.2M223.34K
2026-09-1521.84%2.2M10.2M201.96K
2026-08-3119.78%1.9M9.8M194.23K
2026-08-1417.59%1.7M9.8M188.70K
2026-07-3117.97%1.8M9.8M196.30K
2026-07-1520.43%1.9M9.5M207.80K
2026-06-3022.54%2.1M9.5M194.88K
2026-06-1522.70%2.2M9.5M201.97K
2026-05-2924.83%2.3M9.4M257.48K
2026-05-1527.70%2.6M9.4M270.84K
2026-04-3027.69%2.5M8.9M366.89K
2026-04-1527.53%2.4M8.8M370.07K
2026-03-3123.87%2.4M10.1M377.12K
2026-03-1327.64%2.8M10.1M414.54K
2026-02-2730.57%3.1M10.1M373.22K
2026-02-1336.27%3.7M10.1M383.61K
2026-01-3035.52%3.8M10.6M339.65K
2026-01-1537.49%4.0M10.6M430.03K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.507.5011.900.005.9810.000.000.867-0.3840.007
call15.005.009.500.004.7840.000.000.818-0.3770.009
call17.502.507.000.003.6610.000.000.760-0.3530.011
call20.000.104.902.552.97040.000.000.686-0.3100.012
call22.500.004.900.003.7910.000.000.596-0.2740.013
call25.000.004.901.204.4101.000.000.562-0.3370.013
call30.000.004.903.105.3405.000.000.516-0.4120.014
call35.000.004.900.005.7870.000.000.488-0.4490.014
call40.000.004.900.006.3390.000.000.469-0.4910.014
call45.000.004.900.006.7960.000.000.455-0.5240.014
put12.500.004.900.009.1640.000.00-0.130-0.3760.007
put15.000.004.900.207.35610.000.00-0.182-0.3750.009
put17.500.004.900.905.8641000.00-0.240-0.3510.011
put20.000.004.901.804.58151.000.00-0.314-0.3070.012
put22.500.004.900.003.3800.000.00-0.405-0.2710.013
put25.001.005.500.002.6330.000.00-0.438-0.3340.013
put30.005.8010.000.003.1631.000.00-0.484-0.4090.014
put35.0010.8014.700.003.5710.000.00-0.510-0.4620.014
put40.0015.6020.000.004.3480.000.00-0.529-0.5030.014
put45.0020.5025.400.005.1260.000.00-0.542-0.5360.014

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-29SCHEDULE 13G/ASEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-08-27144Filing for proposed sale of securities under Rule 144.SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-20SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-103Initial statement of beneficial ownership of securities2026-06-08SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090012.35K1
2026-08003.08K2
2026-070000
2026-06006.02K1
2026-050031.95K1
2026-040031.05K1
2026-0300566.56K4
2026-02182.41K200
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC15.00%
TCG Crossover Management, LLC6.39%
BlackRock, Inc.4.57%
First Light Asset Management, LLC4.24%
BAKER BROS. ADVISORS LP3.22%
5AM Venture Management, LLC3.22%
BRAIDWELL LP3.16%
VANGUARD CAPITAL MANAGEMENT LLC2.59%
Aberdeen Group plc2.48%
Vestal Point Capital, LP2.25%

Funds

Fund% owned
abrdn Healthcare Investors4.09%
Fidelity Growth Company Fund3.86%
Select Biotechnology Portfolio2.07%
abrdn Life Sciences Investors1.97%
iShares Russell 2000 ETF1.43%
Fidelity Growth Company K6 Fund1.33%
Fidelity Series Growth Company Fund1.05%
Fidelity Advisor Biotechnology Fund0.64%
Columbia Small Cap Growth Fund0.62%
Fidelity Small Cap Index Fund0.59%

OakChart. TECX. Cached 15 minutes.